5 recruiting, 4 completed, 2 unknown, 1 active not recruiting. 5 Phase 3, 4 Phase 2, 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Phase 4 | 3 | Completed 1, Enrolling by invitation 1, Recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Fasenra: new trials by email Literature Review of Fasenra trials Research Report on Fasenra
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-10-27 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy benralizumab - Severe Eosinophilic Asthma | Recruiting | AstraZeneca | 335 | 2025-12-20 | 2026-09-18 | |
| Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis Fasenra - Allergic Bronchopulmonary Aspergillosis, Severe Asthma | Recruiting | Qianfoshan Hospital | 20 | 2025-09-01 | 2026-04-21 | |
| A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | Recruiting | AstraZeneca | 14 | 2025-04-17 | 2026-10-28 |
| STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 504 | 2024-02-28 | 2026-09-03 |
| Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping Dupilumab, Benralizumab - Moderate to Severe Asthma | Phase 4 | Recruiting | University of California, San Diego | 120 | 2024-02-19 | 2024-08-19 |
| BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Benralizumab - Asthma | Phase 4 | Completed | AstraZeneca | 45 | 2022-10-11 | 2025-03-25 |
| Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI Benralizumab, 129 Xenon - Asthma; Eosinophilic | Not applicable | Active not recruiting | Dr. Grace Parraga | 29 | 2022-03-01 | 2025-08-11 |
| Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) Benralizumab, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 3 | Terminated | AstraZeneca | 12 | 2022-01-18 | 2025-07-14 |
| Benralizumab Initiated During Severe Asthma Attack Benralizumab 30 MG/ML [Fasenra], Placebos - Asthma Attack, Asthma | Phase 2 | Unknown | Singapore General Hospital | 128 | 2021-06-02 | 2021-07-23 |
| Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) Benralizumab, Prednisolone - Asthma, COPD | Phase 2 | Unknown | University of Oxford | 158 | 2021-03-29 | 2024-01-23 |
| Benralizumab for Eosinophilic Gastritis (BEGS) Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 26 | 2018-04-23 | 2022-02-03 |
| Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis Benralizumab, Placebo - Chronic Rhinosinusitis (Diagnosis), Nasal Polyps | Phase 2 | Completed | Johns Hopkins University | 33 | 2017-07-01 | 2021-02-11 |
Asthma (7) · Pulmonary Eosinophilia (5) · Churg-Strauss Syndrome (2) · Eosinophilic enteropathy (2) · Gastroenteritis (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Digestive System Diseases (1) · Disease (1) · Eosinophilia (1) · Gastrointestinal Diseases (1) · Hypereosinophilic Syndrome (1) · Intestinal Diseases (1) · Nasal Polyps (1) · Pulmonary Disease, Chronic Obstructive (1) · Stomach Diseases (1)
AstraZeneca (6) · Children's Hospital Medical Center, Cincinnati (1) · Dr. Grace Parraga (1) · Endeavor Health (1) · Johns Hopkins University (1) · Qianfoshan Hospital (1) · Singapore General Hospital (1) · University of California, San Diego (1) · University of Oxford (1)
United States (8) · Canada (3) · France (3) · Italy (3) · Netherlands (3) · Poland (3) · United Kingdom (3) · Belgium (2) · Brazil (2) · China (2) · India (2) · Israel (2) · Spain (2) · Turkey (Türkiye) (2) · Argentina (1)
Giselle Mosnaim, MD, MS (1) · Grace E Parraga, PhD (1) · HuaHao Shen, Professor (1) · Jody Tversky, MD (1) · Kelan Tantisira, MD (1) · Marc E Rothenberg, MD, PhD (1) · Marc E. Rothenberg, MD, PhD (1) · Mariko Koh (1) · Min Zhang, Professor (1) · Mona Bafadhel, PhD, MBChB (1) · Qian Qi (1)
PMID 25445859, PMID 27609406, PMID 27609408, PMID 31310686, PMID 33595845, PMID 34110505, PMID 35283104, PMID 36781102, PMID 37131265, PMID 37336228, PMID 39615502, PMID 42458446
2018 (1), 2023 (1), R01HL161362 (1)